BlackRock Inc. grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,109,514 shares of the medical research company’s stock after acquiring an additional 105,819 shares during the quarter. BlackRock Inc. owned about 6.68% of Edwards Lifesciences Corporation worth $1,668,309,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Sabal Trust CO increased its stake in shares of Edwards Lifesciences Corporation by 0.5% during the 2nd quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after acquiring an additional 14 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Edwards Lifesciences Corporation by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after acquiring an additional 14 shares during the last quarter. Alexandria Capital LLC increased its stake in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares during the last quarter. M Holdings Securities Inc. increased its stake in shares of Edwards Lifesciences Corporation by 1.5% during the 1st quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock valued at $389,000 after acquiring an additional 62 shares during the last quarter. Finally, First Bank & Trust increased its stake in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. First Bank & Trust now owns 4,439 shares of the medical research company’s stock valued at $525,000 after acquiring an additional 76 shares during the last quarter. 82.36% of the stock is owned by institutional investors.

EW has been the subject of a number of research reports. BidaskClub upgraded Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 22nd. Canaccord Genuity reiterated a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research cut Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Thursday, June 8th. Jefferies Group LLC reiterated a “buy” rating and set a $115.00 target price on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Finally, SunTrust Banks, Inc. boosted their target price on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences Corporation has a consensus rating of “Buy” and an average price target of $120.75.

WARNING: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/16/edwards-lifesciences-corporation-ew-shares-bought-by-blackrock-inc.html.

Edwards Lifesciences Corporation (NYSE:EW) traded up 1.79% during trading on Friday, hitting $113.50. The stock had a trading volume of 1,944,139 shares. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The company’s 50-day moving average is $113.99 and its 200 day moving average is $108.88. The firm has a market cap of $23.97 billion, a PE ratio of 34.43 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.76 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $112.45, for a total value of $3,699,605.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Larry L. Wood sold 18,960 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $111.81, for a total value of $2,119,917.60. The disclosure for this sale can be found here. Insiders sold a total of 163,541 shares of company stock worth $18,712,719 in the last ninety days. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.